Prestige Biologics Order Backlog Tops KRW 30 Billion, Marking Growth Milestone

[Song Young-doo, Edaily Reporter] Prestige Biologics, a contract development and manufacturing organization(CDMO) for biopharmaceuticals, said Sunday its cumulative order volume has surpassed KRW 32 billion, a record high since the company’s founding.

It is the first time the company’s annual orders have exceeded KRW 30 billion. The figure represents more than a 1,500% increase compared to last year’s revenue of KRW 2.1 billion.

A KRW 3.9 billion order announced last week was the company’s first contract this year beyond its parent firm, Prestige Biopharma. While client and product names remain confidential, the company said the deal reflects strong trust with its partners and will support continued growth. The company cited its experience in producing over 100 batches of various biopharmaceuticals as a key factor in securing the contract.

With this momentum, utilization rates across its four plants with a total capacity of 154,000 liters are steadily rising. Plant No. 1 has already exceeded a 70% utilization rate based on maximum batch production. Orders are also being fulfilled at Plants No. 2 and No. 4.

The company expects to expand its production capabilities this year as demand from its parent company and global pharmaceutical firms continues to grow.

Large-scale production of Prestige Biopharma’s lead pipeline drug, Tuznue, is underway at Campus 1, which holds EU Good Manufacturing Practice(GMP) certification. Meanwhile, Plant No. 4 is preparing for U.S. Food and Drug Administration current GMP(cGMP) certification through the production of HD204, which is undergoing regulatory review.

With its order backlog at KRW 32 billion, the company said it is focused on winning large-scale contracts. It is pursuing a two-track strategy: hiring specialized talent and enhancing its quality control systems.

As Prestige Biologics builds a strong CDMO track record, interest from domestic and international clients is growing, raising expectations for additional orders.

“Robust new orders and a solid backlog are increasing plant utilization and driving external growth,” a company official said. “We’ll continue to focus on client acquisition with our single-use bioreactor system, which reduces cross-contamination risk and offers cost and production flexibility.”